IDEAS home Printed from https://ideas.repec.org/e/c/pky20.html
   My authors  Follow this author

Margaret K. Kyle

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Margaret Kyle & Heidi L. Williams, 2017. "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," NBER Working Papers 23068, National Bureau of Economic Research, Inc.

    Cited by:

    1. Otilia Boldea & Bettina Drepper & Zhuojiong Gan, 2020. "Change point estimation in panel data with time‐varying individual effects," Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 35(6), pages 712-727, September.
    2. Madhu Mazumdar & Jashvant V. Poeran & Bart S. Ferket & Nicole Zubizarreta & Parul Agarwal & Ksenia Gorbenko & Catherine K. Craven & Xiaobo (Tony) Zhong & Alan J. Moskowitz & Annetine C. Gelijns & Davi, 2021. "Developing an Institute for Health Care Delivery Science: successes, challenges, and solutions in the first five years," Health Care Management Science, Springer, vol. 24(1), pages 234-243, March.
    3. Joshua Krieger & Danielle Li & Dimitris Papanikolaou, 2022. "Missing Novelty in Drug Development," The Review of Financial Studies, Society for Financial Studies, vol. 35(2), pages 636-679.
    4. Margaret K. Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
    5. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    6. Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.

  2. Arnaud Costinot & Dave Donaldson & Margaret Kyle & Heidi Williams, 2016. "The More We Die, The More We Sell? A Simple Test of the Home-Market Effect," NBER Working Papers 22538, National Bureau of Economic Research, Inc.

    Cited by:

    1. Sharat Ganapati & Rebecca McKibbin, 2019. "Non-Tariff Barriers and Bargaining in Generic Pharmaceuticals," Working Papers gueconwpa~18-18-23, Georgetown University, Department of Economics.
    2. Stephen J. Redding & Esteban Rossi-Hansberg, 2017. "Quantitative Spatial Economics," Annual Review of Economics, Annual Reviews, vol. 9(1), pages 21-58, September.
    3. Proost, Stef & Thisse, Jacques-François, 2019. "What can be learned from spatial economics?," LIDAM Reprints CORE 3089, Université catholique de Louvain, Center for Operations Research and Econometrics (CORE).
    4. Jorge Guzman & Fiona Murray & Scott Stern & Heidi Williams, 2023. "Accelerating Innovation Ecosystems: The Promise and Challenges of Regional Innovation Engines," NBER Chapters, in: Entrepreneurship and Innovation Policy and the Economy, volume 3, pages 9-75, National Bureau of Economic Research, Inc.
    5. Dongin Kim & Sandro Steinbach, 2024. "The Linder hypothesis for foreign direct investment revisited," Review of International Economics, Wiley Blackwell, vol. 32(4), pages 1901-1928, September.
    6. Pamina Koenig, 2017. "Notes on Sigwatch's NGO campaign database," Working Papers halshs-01671758, HAL.
    7. Davis, Colin & Hashimoto, Ken-ichi, 2022. "Productivity growth, industry location patterns and labor market frictions," Regional Science and Urban Economics, Elsevier, vol. 97(C).
    8. Martin Beraja & David Y. Yang & Noam Yuchtman, 2021. "Data-intensive innovation and the State: evidence from AI firms in China," CEP Discussion Papers dp1755, Centre for Economic Performance, LSE.
    9. Xavier Jaravel & Erick Sager, 2019. "What are the Price Effects of Trade? Evidence from the U.S. and Implications for Quantitative Trade Models," 2019 Meeting Papers 1320, Society for Economic Dynamics.
    10. Stephen J Redding, 2020. "Trade and Geography," Working Papers 266, Princeton University, Department of Economics, Center for Economic Policy Studies..
    11. Fajgelbaum,Pablo David & Goldberg,Pinelopi Koujianou & Kennedy,Patrick & Khandelwal,Amit Kumar & Taglioni,Daria, 2022. "The US-China Trade War and Global Reallocations," Policy Research Working Paper Series 9894, The World Bank.
    12. Fabien Candau & Charles Regnacq & Julie Schlick, 2022. "Climate Change, Comparative Advantage and the Water Capability to Produce Agricultural Goods," Working papers of Transitions Energétiques et Environnementales (TREE) hal-03671521, HAL.
    13. Anson Soderbery, 2021. "Trade restrictiveness indexes and welfare: A structural approach," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 54(3), pages 1018-1045, November.
    14. Asier Minondo, 2017. "Fundamental Versus Granular Comparative Advantage: An Analysis Using Chess Data," Kyklos, Wiley Blackwell, vol. 70(3), pages 425-455, August.
    15. Cong Peng, 2019. "Does e-commerce reduce traffic congestion? Evidence from Alibaba Single Day shopping event," CEP Discussion Papers dp1646, Centre for Economic Performance, LSE.
    16. Sophie Hatte & Pamina Koenig, 2020. "The Geography of NGO Activism against Multinational Corporations," PSE-Ecole d'économie de Paris (Postprint) halshs-02491665, HAL.
    17. Berliant, Marcus & Tabuchi, Takatoshi, 2023. "Market size, trade, and productivity reconsidered: Poverty traps and the home market effect," MPRA Paper 117405, University Library of Munich, Germany.
    18. Breinlich, Holger & Leromain, Elsa & Novy, Dennis & Sampson, Thomas, 2022. "Import Liberalization as Export Destruction? Evidence from the United States," The Warwick Economics Research Paper Series (TWERPS) 1413, University of Warwick, Department of Economics.
    19. Peng, Cong, 2019. "Does e-commerce reduce traffic congestion? Evidence from Alibaba Single Day shopping event," LSE Research Online Documents on Economics 103411, London School of Economics and Political Science, LSE Library.
    20. Kevin A. Bryan & Heidi L. Williams, 2021. "Innovation: Market Failures and Public Policies," NBER Working Papers 29173, National Bureau of Economic Research, Inc.
    21. Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2018. "Characterizing the Drug Development Pipeline for Precision Medicines," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 115-157, National Bureau of Economic Research, Inc.
    22. Colin Davis & Ken‐ichi Hashimoto, 2023. "Innovation offshoring and reshoring with fully endogenous growth," Southern Economic Journal, John Wiley & Sons, vol. 90(1), pages 90-120, July.
    23. Jordan J. Norris, 2021. "The Home Market Effects in a Home-Biased Geography," Working Papers 20210072, New York University Abu Dhabi, Department of Social Science, revised Sep 2021.
    24. Jaravel, Xavier & Sager, Erick, 2019. "What are the price effects of trade? Evidence from the US for quantitative trade models," LSE Research Online Documents on Economics 103402, London School of Economics and Political Science, LSE Library.
    25. Jaravel, Xavier Laurent & Sager, Erick, 2019. "What are the price effects of trade? Evidence from the US and implications for quantitative trade models," LSE Research Online Documents on Economics 121819, London School of Economics and Political Science, LSE Library.
    26. Lashkaripour, Ahmad, 2020. "Discrete trade," Journal of International Economics, Elsevier, vol. 126(C).

  3. Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.

    Cited by:

    1. Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2014. "The Market Impacts Of Pharmaceutical Product Patents In Developing Countries: Evidence From India," Discussion Papers 14-005, Stanford Institute for Economic Policy Research.
    2. Tang, Chang & Xu, Yuanyuan & Hao, Yu & Wu, Haitao & Xue, Yan, 2021. "What is the role of telecommunications infrastructure construction in green technology innovation? A firm-level analysis for China," Energy Economics, Elsevier, vol. 103(C).
    3. Heidi L. Williams, 2017. "How Do Patents Affect Research Investments?," NBER Working Papers 23088, National Bureau of Economic Research, Inc.
    4. Roger Bate & Ginger Zhe Jin & Aparna Mathur & Amir Attaran, 2014. "Poor Quality Drugs and Global Trade: A Pilot Study," NBER Working Papers 20469, National Bureau of Economic Research, Inc.
    5. Margaret Kyle & Heidi Williams, 2016. "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," Post-Print hal-01448505, HAL.
    6. Dubois, Pierre & Lefouili, Yassine & Straub, Stéphane, 2019. "Pooled Procurement of Drugs in Low and Middle Income Countries," TSE Working Papers 19-999, Toulouse School of Economics (TSE), revised Dec 2020.
    7. Kamal Saggi, 2016. "Trade, Intellectual Property Rights, and the World Trade Organization," Vanderbilt University Department of Economics Working Papers 16-00014, Vanderbilt University Department of Economics.
    8. Bond, Eric W. & Saggi, Kamal, 2020. "Patent protection in developing countries and global welfare: WTO obligations versus flexibilities," Journal of International Economics, Elsevier, vol. 122(C).
    9. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
    10. Evangelia Chalioti & Kyriakos Drivas & Sarantis Kalyvitis & Margarita Katsimi, 2020. "Innovation, patents and trade: A firm‐level analysis," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 53(3), pages 949-981, August.
    11. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    12. Massimo Florio & Chiara Pancotti, 2022. "European pharmaceutical research and development. Could a public infrastructure overcome market failures?," Working Papers 202202, CSIL Centre for Industrial Studies.
    13. Heidi L. Williams, 2016. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
    14. Danlin Shen & Carl R. Chen & Xinyan Yan & Zhihong Yi, 2022. "Do credit market accessibility and legal protection shape corporate innovation?," Journal of Financial Research, Southern Finance Association;Southwestern Finance Association, vol. 45(3), pages 719-754, September.
    15. Nancy Gallini, 2017. "Do patents work? Thickets, trolls and antibiotic resistance," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 50(4), pages 893-926, November.
    16. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
    17. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.
    18. Trachtenberg Danielle & Kaplan Warren A. & Wirtz Veronika J. & Gallagher Kevin P., 2019. "The Effects of Trade Agreements on Imports of Biologics: Evidence from Chile," Journal of Globalization and Development, De Gruyter, vol. 10(2), pages 1-21, December.

  4. Allain, Marie-Laure & Henry, Emeric & Kyle, Margaret, 2013. "Competition and the Efficiency of Markets for Technology," IDEI Working Papers 784, Institut d'Économie Industrielle (IDEI), Toulouse.

    Cited by:

    1. Ashish Arora & Andrea Fosfuri & Thomas Roende, 2018. "Waiting for the Payday? The Market for Startups and the Timing of Entrepreneurial Exit," NBER Working Papers 24350, National Bureau of Economic Research, Inc.
    2. Norbäck, Pehr-Johan & Persson, Lars & Svensson, Roger, 2017. "Verifying High Quality: Entry for Sale," Working Paper Series 1186, Research Institute of Industrial Economics.
    3. Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
    4. Choné, Philippe & Linnemer, Laurent, 2020. "Linear demand systems for differentiated goods: Overview and user’s guide," International Journal of Industrial Organization, Elsevier, vol. 73(C).
    5. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2016. "Competition and the Efficiency of Markets for Technology," Management Science, INFORMS, vol. 62(4), pages 1000-1019, April.
    6. Jeon, Haejun & Nishihara, Michi, 2018. "Optimal patent policy in the presence of vertical separation," European Journal of Operational Research, Elsevier, vol. 270(2), pages 682-697.
    7. Benoit Voudon, 2019. "Technology Adoption under Asymmetric Market Structure," Trinity Economics Papers tep0819, Trinity College Dublin, Department of Economics.
    8. Peters, Bettina & Marks, Hannes & Trunschke, Markus & Grimpe, Christoph & Sofka, Wolfgang & Czarnitzki, Dirk, 2023. "Schwerpunktstudie Technologiemärkte," Studien zum deutschen Innovationssystem 9-2023, Expertenkommission Forschung und Innovation (EFI) - Commission of Experts for Research and Innovation, Berlin.
    9. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    10. Philippe Choné & Laurent Linnemer, 2019. "The quasilinear quadratic utility model: An overview," Working Papers hal-02318633, HAL.
    11. Li, Qing & Zhang, Huaige & Hong, Xianpei, 2020. "Knowledge structure of technology licensing based on co-keywords network: A review and future directions," International Review of Economics & Finance, Elsevier, vol. 66(C), pages 154-165.
    12. Deepak Hegde & Hong Luo, 2018. "Patent Publication and the Market for Ideas," Management Science, INFORMS, vol. 64(2), pages 652-672, February.
    13. Louis-Sidois, Charles, 2024. "Buying winners," Games and Economic Behavior, Elsevier, vol. 143(C), pages 1-11.
    14. Jean-Etienne de Bettignies & Hua Fang Liu & David T. Robinson & Bulat Gainullin, 2023. "Competition and Innovation in Markets for Technology," Management Science, INFORMS, vol. 69(8), pages 4753-4773, August.
    15. Yan Anthea Zhang & Zhuo Emma Chen & Yuandi Wang, 2021. "Which patents to use as loan collaterals? The role of newness of patents' external technology linkage," Strategic Management Journal, Wiley Blackwell, vol. 42(10), pages 1822-1849, October.
    16. Arora, Ashish & Fosfuri, Andrea & Rønde, Thomas, 2024. "The missing middle: Value capture in the market for startups," Research Policy, Elsevier, vol. 53(3).
    17. Kim, Young-Choon & Kotha, Reddi & Rhee, Mooweon, 2024. "Do firms with technological capabilities rush in? Evidence from the timing of licensing of Stanford inventions," Journal of Business Research, Elsevier, vol. 178(C).

  5. Kyle, Margaret & Allain, Marie-Laure, 2011. "Inefficiencies in technology transfer: theory and empirics," CEPR Discussion Papers 8206, C.E.P.R. Discussion Papers.

    Cited by:

    1. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2011. "Inefficiencies in the sale of ideas: theory and empirics," Working Papers hal-00639128, HAL.
    2. Hong Luo, 2014. "When to Sell Your Idea: Theory and Evidence from the Movie Industry," Management Science, INFORMS, vol. 60(12), pages 3067-3086, December.
    3. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2016. "Competition and the Efficiency of Markets for Technology," Management Science, INFORMS, vol. 62(4), pages 1000-1019, April.
    4. Simon Wakeman, 2012. "How does obtaining intellectual property rights impact technology commercialization strategy for start-up innovators? Reconciling the effects on licensing vs. financing," ESMT Research Working Papers ESMT-12-03 (R1), ESMT European School of Management and Technology, revised 11 Jul 2012.
    5. Seongkyoon Jeong & Sungki Lee, 2015. "Strategic timing of academic commercialism: evidence from technology transfer," The Journal of Technology Transfer, Springer, vol. 40(6), pages 910-931, December.

  6. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2011. "Inefficiencies in the sale of ideas: theory and empirics," Working Papers hal-00639128, HAL.

    Cited by:

    1. Joshua S. Gans, 2014. "Negotiating for the Market," NBER Working Papers 20559, National Bureau of Economic Research, Inc.

  7. Kyle, Margaret & McGahan, Anita M, 2011. "Investments in Pharmaceuticals Before and After TRIPS," CEPR Discussion Papers 8371, C.E.P.R. Discussion Papers.

    Cited by:

    1. Javad Moradpour & Aidan Hollis, 2020. "Patient income and health innovation," Health Economics, John Wiley & Sons, Ltd., vol. 29(12), pages 1795-1803, December.
    2. Emmanuelle Auriol & Sara Biancini & Rodrigo Paillacar, 2023. "Intellectual property rights protection and trade: an empirical analysis," Post-Print hal-03947266, HAL.
    3. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    4. Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2014. "The Market Impacts Of Pharmaceutical Product Patents In Developing Countries: Evidence From India," Discussion Papers 14-005, Stanford Institute for Economic Policy Research.
    5. Ganguly, Madhuparna, 2021. "Competition and Innovation: the effects of scientist mobility and stronger patent rights," MPRA Paper 107831, University Library of Munich, Germany.
    6. Sarath Balachandran & Exequiel Hernandez, 2019. "Do Institutional Reforms Perpetuate or Mitigate the Matthew Effect? Intellectual Property Rights and Access to International Alliances," Strategy Science, INFORMS, vol. 4(2), pages 151-174, June.
    7. Iizuka, Toshiaki & Uchida, Gyo, 2017. "Promoting innovation in small markets: Evidence from the market for rare and intractable diseases," Journal of Health Economics, Elsevier, vol. 54(C), pages 56-65.
    8. Margaret K. Kyle, 2019. "The Single Market in Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 55(1), pages 111-135, August.
    9. Ganguly, Madhuparna, 2021. "Stronger Patent Regime, Innovation and Scientist Mobility," MPRA Paper 107635, University Library of Munich, Germany.
    10. Silvia Balia & Sara Pau & Silvana Robone, 2021. "Intellectual property rights protection and health: the case of tuberculosis," RIEDS - Rivista Italiana di Economia, Demografia e Statistica - The Italian Journal of Economic, Demographic and Statistical Studies, SIEDS Societa' Italiana di Economia Demografia e Statistica, vol. 75(3), pages 149-160, July-Sept.
    11. Roger Bate & Ginger Zhe Jin & Aparna Mathur & Amir Attaran, 2014. "Poor Quality Drugs and Global Trade: A Pilot Study," NBER Working Papers 20469, National Bureau of Economic Research, Inc.
    12. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
    13. Emmanuelle Auriol & Sara Biancini & Rodrigo Paillacar, 2019. "Universal intellectual property rights: Too much of a good thing?," Post-Print hal-03475023, HAL.
    14. F. Montobbio & A. Primi & Valerio Sterzi, 2015. "IPRs and international knowledge flows: Evidence from six large emerging countries," Post-Print hal-02486325, HAL.
    15. Ahn, Kiefer & Trujillo, Antonio & Gibbons, Jason & Bennett, Charles L. & Anderson, Gerard, 2023. "Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry," International Review of Law and Economics, Elsevier, vol. 76(C).
    16. Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
    17. Kamal Saggi, 2016. "Trade, Intellectual Property Rights, and the World Trade Organization," Vanderbilt University Department of Economics Working Papers 16-00014, Vanderbilt University Department of Economics.
    18. Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
    19. Anna-Maria Aksan, 2013. "Appropriate Health R&D and Intellectual Property Rights Reform in Developing Countries," Economica, London School of Economics and Political Science, vol. 80(319), pages 475-495, July.
    20. OKADA, Yoshimi & 岡田, 吉美 & NAGAOKA, Sadao & 長岡, 貞男, 2016. "Global spread of pharmaceutical patent protections: micro evidence from the international equivalents of the drug patents in Japan," IIR Working Paper 16-07, Institute of Innovation Research, Hitotsubashi University.
    21. Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
    22. Marek Ignaszak & Petr Sedlácek, 2021. "Profitability, Productivity and Growth," Economics Series Working Papers 937, University of Oxford, Department of Economics.
    23. Carliss Y. Baldwin & Joachim Henkel, 2015. "Modularity and intellectual property protection," Strategic Management Journal, Wiley Blackwell, vol. 36(11), pages 1637-1655, November.
    24. Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
    25. Shinjinee Chattopadhyay & Janet Bercovitz, 2020. "When one door closes, another door opens … for some: Evidence from the post‐TRIPS Indian pharmaceutical industry," Strategic Management Journal, Wiley Blackwell, vol. 41(6), pages 988-1022, June.
    26. Chatterjee, Chirantan & Kubo, Kensuke & Pingali, Viswanath, 2015. "The consumer welfare implications of governmental policies and firm strategy in markets for medicines," Journal of Health Economics, Elsevier, vol. 44(C), pages 255-273.
    27. Papageorgiadis, Nikolaos & Sofka, Wolfgang, 2020. "Patent enforcement across 51 countries – Patent enforcement index 1998–2017," Journal of World Business, Elsevier, vol. 55(4).
    28. Yi Qian, 2014. "Counterfeiters: Foes or Friends? How Counterfeits Affect Sales by Product Quality Tier," Management Science, INFORMS, vol. 60(10), pages 2381-2400, October.
    29. Hu, Xiaotian & Yin, Xiaopeng, 2022. "Do stronger intellectual property rights protections raise productivity within the context of trade liberalization? Evidence from China," Economic Modelling, Elsevier, vol. 110(C).
    30. Mujaheed Shaikh & Afschin Gandjour, 2019. "Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two‐step instrumental variables strategy," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 101-122, January.
    31. Gao, Wenlian & Chou, Julia, 2015. "Innovation efficiency, global diversification, and firm value," Journal of Corporate Finance, Elsevier, vol. 30(C), pages 278-298.
    32. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    33. Meyer, Camille & Naicker, Kiruben, 2023. "Collective intellectual property of Indigenous peoples and local communities: Exploring power asymmetries in the rooibos geographical indication and industry-wide benefit-sharing agreement," Research Policy, Elsevier, vol. 52(9).
    34. Heidi L. Williams, 2016. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
    35. David Dranove & Craig Garthwaite & Manuel I. Hermosilla, 2020. "Expected Profits and The Scientific Novelty of Innovation," NBER Working Papers 27093, National Bureau of Economic Research, Inc.
    36. Mary K. Olson & Nina Yin, 2018. "Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity," American Journal of Health Economics, University of Chicago Press, vol. 4(3), pages 321-357, Summer.
    37. Gaessler, Fabian & Wagner, Stefan, 2019. "Patents, Data Exclusivity, and the Development of New Drugs," Rationality and Competition Discussion Paper Series 176, CRC TRR 190 Rationality and Competition.
    38. Kyle, Margaret & Ridley, David & Zhang, Su, 2017. "Strategic Interaction Among Governments in the Provision of a Global Public Good," CEPR Discussion Papers 12419, C.E.P.R. Discussion Papers.
    39. Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
    40. Frankovic, Ivan & Kuhn, Michael, 2023. "Health insurance, endogenous medical progress, health expenditure growth, and welfare," Journal of Health Economics, Elsevier, vol. 87(C).
    41. Kalcheva, Ivalina & McLemore, Ping & Pant, Shagun, 2018. "Innovation: The interplay between demand-side shock and supply-side environment," Research Policy, Elsevier, vol. 47(2), pages 440-461.
    42. Nancy Gallini, 2017. "Do patents work? Thickets, trolls and antibiotic resistance," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 50(4), pages 893-926, November.
    43. Dan Prud’homme & Tony W. Tong & Nianchen Han, 2021. "A stakeholder-based view of the evolution of intellectual property institutions," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 52(4), pages 773-802, June.
    44. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
    45. Auriol, Emmanuelle & Biancini, Sara & Paillacar, Rodrigo, 2015. "Intellectual Property Rights Protection and Trade," CEPR Discussion Papers 10602, C.E.P.R. Discussion Papers.
    46. Sieds, 2021. "Complete Volume LXXV n. 3 2021," RIEDS - Rivista Italiana di Economia, Demografia e Statistica - The Italian Journal of Economic, Demographic and Statistical Studies, SIEDS Societa' Italiana di Economia Demografia e Statistica, vol. 75(3), pages 1-194, July-Sept.
    47. Loitongbam, Bishwanjit Singh, 2016. "Impact of TRIPS and RTAs on the Indian Pharmaceutical Product Exports," MPRA Paper 75764, University Library of Munich, Germany, revised 27 May 2016.
    48. Margaret K. Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
    49. Valeria Arza & Agustina Colonna, 2021. "Exploring the links between research demand and supply: The case of Chagas," SPRU Working Paper Series 2021-01, SPRU - Science Policy Research Unit, University of Sussex Business School.
    50. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    51. Maskus, Keith E. & Milani, Sahar & Neumann, Rebecca, 2019. "The impact of patent protection and financial development on industrial R&D," Research Policy, Elsevier, vol. 48(1), pages 355-370.
    52. Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.
    53. Loitongbam, Bishwanjit Singh, 2016. "Globalization and Innovation in the Indian Pharmaceutical Industry," MPRA Paper 75925, University Library of Munich, Germany, revised 27 May 2016.
    54. Joel Blit & Mauricio Zelaya, "undated". "The impact of patent protection on R&D. Evidence using export markets," Working Papers 17010, University of Waterloo, Department of Economics.
    55. Ernst Berndt & Nathan Blalock & Iain Cockburn, 2011. "Diffusion of New Drugs in the Post-TRIPS Era," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 203-224.
    56. Wen Chen, 2017. "Do stronger intellectual property rights lead to more R&D-intensive imports?," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 26(7), pages 865-883, October.
    57. Federico Nutarelli & Massimo Riccaboni & Andrea Morescalchi, 2021. "Product recalls, market size and innovation in the pharmaceutical industry," Papers 2111.15389, arXiv.org.
    58. Hasan, Iftekhar & Khalil, Fahad & Sun, Xian, 2017. "The impacts of intellectual property rights protection on cross-border M&As," Bank of Finland Research Discussion Papers 17/2017, Bank of Finland.
    59. Madan Dhanora & Ruchi Sharma & Walter G. Park, 2021. "Technological Innovations and Market Power: A Study of Indian Pharmaceutical Industry," Millennial Asia, , vol. 12(1), pages 5-34, April.
    60. Shahnawaz Sheikh, 2012. "The Optimal Timing of Compulsory Licensing: A Story of Thailand's Winter of Discontent," Global Economy Journal, De Gruyter, vol. 12(4), pages 1-19, December.
    61. Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.
    62. Zhang, Xuan & Nie, Huihua, 2021. "Public health insurance and pharmaceutical innovation: Evidence from China," Journal of Development Economics, Elsevier, vol. 148(C).
    63. David Dranove & Craig Garthwaite & Manuel Hermosilla, 2022. "Does consumer demand pull scientifically novel drug innovation?," RAND Journal of Economics, RAND Corporation, vol. 53(3), pages 590-638, September.

  8. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2011. "Inefficiencies in technology transfer: theory and empirics," SciencePo Working papers Main hal-03473787, HAL.

    Cited by:

    1. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2011. "Inefficiencies in the sale of ideas: theory and empirics," Working Papers hal-00639128, HAL.
    2. Hong Luo, 2014. "When to Sell Your Idea: Theory and Evidence from the Movie Industry," Management Science, INFORMS, vol. 60(12), pages 3067-3086, December.
    3. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2016. "Competition and the Efficiency of Markets for Technology," Management Science, INFORMS, vol. 62(4), pages 1000-1019, April.
    4. Simon Wakeman, 2012. "How does obtaining intellectual property rights impact technology commercialization strategy for start-up innovators? Reconciling the effects on licensing vs. financing," ESMT Research Working Papers ESMT-12-03 (R1), ESMT European School of Management and Technology, revised 11 Jul 2012.
    5. Seongkyoon Jeong & Sungki Lee, 2015. "Strategic timing of academic commercialism: evidence from technology transfer," The Journal of Technology Transfer, Springer, vol. 40(6), pages 910-931, December.

  9. Margaret K. Kyle, 2007. "Strategic Responses to Parallel Trade," NBER Working Papers 12968, National Bureau of Economic Research, Inc.

    Cited by:

    1. Susan J. Méndez, 2016. "Parallel Trade of Pharmaceuticals: The Danish Market for Statins," Melbourne Institute Working Paper Series wp2016n08, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
    2. Birg, Laura, 2022. "Pharmaceutical Regulation under Market Integration through Parallel Trade," VfS Annual Conference 2022 (Basel): Big Data in Economics 264128, Verein für Socialpolitik / German Economic Association.
    3. Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
    4. Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
    5. Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
    6. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
    7. Dubois, P.; & Majewska, G.; & Reig, V.;, 2023. "Drug Shortages: Empirical Evidence from France," Health, Econometrics and Data Group (HEDG) Working Papers 23/07, HEDG, c/o Department of Economics, University of York.
    8. Margaret K. Kyle, 2019. "The Single Market in Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 55(1), pages 111-135, August.
    9. Reisinger, Markus & Saurí, Lluís & Zenger, Hans, 2019. "Parallel imports, price controls, and innovation," Journal of Health Economics, Elsevier, vol. 66(C), pages 163-179.
    10. Bruno van Pottelsberghe, 2009. "Economic incongruities in the European patent system," Bruegel Working Papers 226, Bruegel.
    11. Laura Birg, 2024. "The design of external reference pricing schemes and the choice of reference countries and pricing rules," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 57(4), pages 1182-1202, November.
    12. Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015. "Price regulation and parallel imports of pharmaceuticals," Journal of Public Economics, Elsevier, vol. 129(C), pages 92-105.
    13. Hamilton, Jonathan H., 2012. "The effect of Canadian imports on prescription drug prices in the U.S," Regional Science and Urban Economics, Elsevier, vol. 42(6), pages 1003-1008.
    14. Pamina Koenig & Megan Macgarvie, 2009. "Regulatory policy and the location of bio-pharmaceutical FDI in Europe," Working Papers halshs-00566800, HAL.
    15. Frank Mueller-Langer, 2014. "Copyright and parallel trade," Chapters, in: Richard Watt (ed.), Handbook on the Economics of Copyright, chapter 16, pages 287-310, Edward Elgar Publishing.
    16. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    17. Granlund, David & Yesim Köksal, Miyase, 2012. "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?," HUI Working Papers 59, HUI Research.
    18. Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
    19. Pavel Ciaian & Federica Di Marcantonio & Liesbeth Colen & Kjersti Nes & Jesus Barreiro-Hurle & François J. Dessart & Luisa Menapace & Carlo Russo & Annarita Colamatteo & Negin Fathinejad & Maria Anna , 2020. "Economic analyses of differences in composition of seemingly identical branded food products in the Single Market," JRC Research Reports JRC120297, Joint Research Centre.
    20. Joan Costa-Font & Alistair McGuire & Nebibe Varol, 2015. "Regulation effects on the adoption of new medicines," Empirical Economics, Springer, vol. 49(3), pages 1101-1121, November.
    21. David Granlund, 2022. "The Price Effects of Competition from Parallel Imports and Therapeutic Alternatives: Using Dynamic Models to Estimate the Causal Effect on the Extensive and Intensive Margins," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 60(1), pages 63-92, February.
    22. Granlund, David & Köksal, Miyase Yesim, 2011. "Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?," HUI Working Papers 49, HUI Research.
    23. Granlund, David & Yesim Köksal, Miyase, 2011. "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?," Umeå Economic Studies 831, Umeå University, Department of Economics.
    24. Costa-Font, Joan, 2015. "Is medicines parallel trade ‘regulatory arbitrage’?," LSE Research Online Documents on Economics 60963, London School of Economics and Political Science, LSE Library.
    25. Granlund, David & Yesim Köksal, Miyase, 2011. "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals. What's blame? Derogation or perception?," Working Papers in Economics 499, University of Gothenburg, Department of Economics.
    26. Richard Pomfret & Keith Maskus, 2014. "The New Globalisation of Intellectual Property Rights: What's New This Time?," Australian Economic History Review, Economic History Society of Australia and New Zealand, vol. 54(3), pages 262-284, November.
    27. Granlund, David, 2012. "The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals," HUI Working Papers 75, HUI Research.
    28. Varol, Nebibe & Costa-i-Font, Joan & McGuire, Alistair, 2010. "Do international launch strategies of pharmaceutical corporations respond to changes in the regulatory environment?," LSE Research Online Documents on Economics 29972, London School of Economics and Political Science, LSE Library.
    29. Breinlich, Holger & Nocke, Volker & Schutz, Nicolas, 2017. "International aspects of merger policy: A survey," International Journal of Industrial Organization, Elsevier, vol. 50(C), pages 415-429.
    30. Kjersti Nes & Pavel Ciaian & Federica Di Marcantonio, 2020. "Economic determinants of differences in the composition of seemingly identical branded food products in the EU," JRC Research Reports JRC119221, Joint Research Centre.
    31. Dubois, Pierre & Majewska, Gosia & Reig, Valentina, 2023. "Drug Shortages: Empirical Evidence from France," TSE Working Papers 23-1417, Toulouse School of Economics (TSE).
    32. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    33. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
    34. Nikolsko-Rzhevskyy, Alex & Ogrokhina, Olena, 2018. "Behavior of retail prices in common currency areas: The case of the Eurozone," Economic Modelling, Elsevier, vol. 69(C), pages 49-57.
    35. Granlund, David & Yesim Köksal, Miyase, 2011. "Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals," Working Papers in Economics 496, University of Gothenburg, Department of Economics.
    36. Shen Guo & Bin Hu & Hai Zhong, 2013. "Impact of parallel trade on pharmaceutical firm’s profits: rise or fall?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 345-355, April.

  10. Jeffrey L. Furman & Margaret K. Kyle & Iain M. Cockburn & Rebecca Henderson, 2006. "Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research," NBER Working Papers 12509, National Bureau of Economic Research, Inc.

    Cited by:

    1. Elisa Giuliani & Arianna Martinelli & Roberta Rabellotti, 2015. "Is Co-Invention Expediting Technological Catch Up? A Study of Collaboration between Emerging Country Firms and EU inventors," LEM Papers Series 2015/10, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    2. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
    3. Anders Brostrom & Maureen McKelvey & Christian Sandstrom, 2009. "Investing in Localized Relationships with Universities: What are the Benefits for R&D Subsidiaries of Multinational Enterprises?," Industry and Innovation, Taylor & Francis Journals, vol. 16(1), pages 59-78.
    4. Marie‐Laure Cabon‐Dhersin & Romain Gibert, 2020. "R&D cooperation, proximity and distribution of public funding between public and private research sectors," Manchester School, University of Manchester, vol. 88(6), pages 773-800, December.
    5. Kirk B. Doran & George J. Borjas, 2012. "Cognitive Mobility - Labor Market Responses to Supply Shocks in the Space of Ideas," Working Papers 019, University of Notre Dame, Department of Economics, revised Nov 2012.
    6. Zhai, Zhe & Ghosal, Vivek, 2022. "Internationalization of innovation and firm performance in the pharmaceutical industry," International Review of Economics & Finance, Elsevier, vol. 80(C), pages 882-905.
    7. Iain M. Cockburn & Matthew J. Slaughter, 2010. "The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions," NBER Chapters, in: Innovation Policy and the Economy, Volume 10, pages 129-157, National Bureau of Economic Research, Inc.
    8. Marie-Laure Cabon-Dhersin & Emmanuelle Taugourdeau, 2018. "Location and research activities organization: Could public/private cooperation be harmful?," Post-Print hal-02023666, HAL.
    9. Nishimura, Junichi & Okamuro, Hiroyuki, 2012. "Subsidy and networking: The effects of direct and indirect support programs of the cluster policy," Working Paper Series 22, Center for Interfirm Network, Institute of Economic Research, Hitotsubashi University.
    10. Graddy-Reed, Alexandra, 2020. "Getting ahead in the race for a cure: How nonprofits are financing biomedical R&D," Research Policy, Elsevier, vol. 49(8).
    11. Moaniba, Igam M. & Su, Hsin-Ning & Lee, Pei-Chun, 2019. "On the drivers of innovation: Does the co-evolution of technological diversification and international collaboration matter?," Technological Forecasting and Social Change, Elsevier, vol. 148(C).
    12. Aija Leiponen & Constance E. Helfat, 2011. "Location, Decentralization, and Knowledge Sources for Innovation," Organization Science, INFORMS, vol. 22(3), pages 641-658, June.
    13. Nishimura, Junichi & Okamuro, Hiroyuki & 岡室, 博之, 2009. "R&D productivity and the organization of cluster policy : An empirical evaluation of the Industrial Cluster Project in Japan," CCES Discussion Paper Series 4_v2, Center for Research on Contemporary Economic Systems, Graduate School of Economics, Hitotsubashi University.
    14. Bettina Becker, 2015. "Public R&D Policies And Private R&D Investment: A Survey Of The Empirical Evidence," Journal of Economic Surveys, Wiley Blackwell, vol. 29(5), pages 917-942, December.
    15. Daniel Gama e Colombo & Jorge Martinez-Vazquez, 2019. "Fiscal Decentralization and Public R&D Policy: A Country Panel Analysis," International Center for Public Policy Working Paper Series, at AYSPS, GSU paper1918, International Center for Public Policy, Andrew Young School of Policy Studies, Georgia State University.
    16. Livanis, Grigorios & Lamin, Anna, 2016. "Knowledge, Proximity and R&D Exodus," Research Policy, Elsevier, vol. 45(1), pages 8-26.
    17. Su, Hsin-Ning, 2017. "Collaborative and Legal Dynamics of International R&D- Evolving Patterns in East Asia," Technological Forecasting and Social Change, Elsevier, vol. 117(C), pages 217-227.
    18. Yuri Jo & Won Young Chung & Daeho Lee, 2020. "The capability‐enhancing role of government‐driven industrial districts for new technology‐based firms in South Korea," Asia and the Pacific Policy Studies, Wiley Blackwell, vol. 7(3), pages 306-321, September.
    19. Wuestman, Mignon L. & Hoekman, Jarno & Frenken, Koen, 2019. "The geography of scientific citations," Research Policy, Elsevier, vol. 48(7), pages 1771-1780.
    20. Jaana Rahko, 2016. "Internationalization of corporate R&D activities and innovation performance," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 25(6), pages 1019-1038.
    21. Marie-Laure Cabon-Dhersin & Emmanuelle Taugourdeau, 2015. "Research clusters: How public subsidies matter?," Post-Print hal-01159523, HAL.
    22. Rene Belderbos & Bart Leten & Shinya Suzuki, 2009. "Does Excellence in Academic Research Attract Foreign R&D?," Global COE Hi-Stat Discussion Paper Series gd09-079, Institute of Economic Research, Hitotsubashi University.
    23. Anna Giunta & Filippo M. Pericoli & Eleonora Pierucci, 2016. "University–Industry collaboration in the biopharmaceuticals: the Italian case," The Journal of Technology Transfer, Springer, vol. 41(4), pages 818-840, August.
    24. Alonso-Martínez, Daniel, 2018. "Social progress and international patent collaboration," Technological Forecasting and Social Change, Elsevier, vol. 134(C), pages 169-177.
    25. Chris Forman & Nicolas van Zeebroeck, 2012. "From Wires to Partners: How the Internet Has Fostered R&D Collaborations Within Firms," Management Science, INFORMS, vol. 58(8), pages 1549-1568, August.
    26. Bettina Becker, 2013. "The Determinants of R&D Investment: A Survey of the Empirical Research," Discussion Paper Series 2013_09, Department of Economics, Loughborough University, revised Sep 2013.
    27. Hart E. Posen & John S. Chen, 2013. "An Advantage of Newness: Vicarious Learning Despite Limited Absorptive Capacity," Organization Science, INFORMS, vol. 24(6), pages 1701-1716, December.
    28. David B. Ridley, 2009. "Herding versus Hotelling: Market Entry with Costly Information," Levine's Working Paper Archive 814577000000000174, David K. Levine.
    29. Matija Rojec & Mark Knell, 2018. "Why Is There A Lack Of Evidence On Knowledge Spillovers From Foreign Direct Investment?," Journal of Economic Surveys, Wiley Blackwell, vol. 32(3), pages 579-612, July.
    30. Belderbos, René & Mohnen, Pierre, 2020. "Inter-sectoral and international R&D spillovers," MERIT Working Papers 2020-047, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    31. Laura Abramovsky, 2015. "Global engagement in R&D: a portrait of biopharmaceutical patenting firms," IFS Working Papers W15/18, Institute for Fiscal Studies.
    32. Rene Belderbos & Vincent Van Roy & Bart Leten & Bart Thijs, 2014. "Academic Research Strengths and Multinational Firms' Foreign R&D Location Decisions: Evidence from R&D Investments in European Regions," Environment and Planning A, , vol. 46(4), pages 920-942, April.
    33. Isabel Tecu, 2013. "The Location of Industrial Innovation: Does Manufacturing Matter?," Working Papers 13-09, Center for Economic Studies, U.S. Census Bureau.
    34. Eleonora Pierucci, 2015. "University-industry linkages. Among italian regions: a supply-demand analysis," RIVISTA DI ECONOMIA E STATISTICA DEL TERRITORIO, FrancoAngeli Editore, vol. 2015(2), pages 5-33.
    35. Okamuro, Hiroyuki & Nishimura, Junichi, 2011. "Management of Cluster Policies: Case Studies of Japanese, German, and French Bio-clusters," CEI Working Paper Series 2011-7, Center for Economic Institutions, Institute of Economic Research, Hitotsubashi University.
    36. Sanwar A. Sunny & Cheng Shu, 2019. "Investments, incentives, and innovation: geographical clustering dynamics as drivers of sustainable entrepreneurship," Small Business Economics, Springer, vol. 52(4), pages 905-927, April.
    37. Ashish Arora & Michelle Gittelman & Sarah Kaplan & John Lynch & Will Mitchell & Nicolaj Siggelkow & Juan Alcácer & Minyuan Zhao, 2016. "Zooming in: A practical manual for identifying geographic clusters," Strategic Management Journal, Wiley Blackwell, vol. 37(1), pages 10-21, January.
    38. Picone, Gabriel A. & Ridley, David B. & Zandbergen, Paul A., 2009. "Distance decreases with differentiation: Strategic agglomeration by retailers," International Journal of Industrial Organization, Elsevier, vol. 27(3), pages 463-473, May.
    39. Catini, Roberto & Karamshuk, Dmytro & Penner, Orion & Riccaboni, Massimo, 2015. "Identifying geographic clusters: A network analytic approach," Research Policy, Elsevier, vol. 44(9), pages 1749-1762.
    40. Cantner, Uwe & Rake, Bastian, 2014. "International research networks in pharmaceuticals: Structure and dynamics," Research Policy, Elsevier, vol. 43(2), pages 333-348.
    41. Daniel Tzabbar & Alex Vestal, 2015. "Bridging the Social Chasm in Geographically Distributed R&D Teams: The Moderating Effects of Relational Strength and Status Asymmetry on the Novelty of Team Innovation," Organization Science, INFORMS, vol. 26(3), pages 811-829, June.
    42. Hsin-Ning Su, 2017. "Global Interdependence of Collaborative R&D-Typology and Association of International Co-Patenting," Sustainability, MDPI, vol. 9(4), pages 1-28, April.
    43. Rouven E. Haschka & Helmut Herwartz, 2022. "Endogeneity in pharmaceutical knowledge generation: An instrument‐free copula approach for Poisson frontier models," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 31(4), pages 942-960, November.
    44. Massimiliano Ferrara & Roberto Mavilia & Bruno Antonio Pansera, 2017. "Extracting knowledge patterns with a social network analysis approach: an alternative methodology for assessing the impact of power inventors," Scientometrics, Springer;Akadémiai Kiadó, vol. 113(3), pages 1593-1625, December.
    45. Juan Alcácer & Minyuan Zhao, 2013. "Zooming In: A Practical Manual for Identifying Geographic Clusters," Harvard Business School Working Papers 14-042, Harvard Business School.

  11. Allen N. Berger & Margaret K. Kyle & Joseph M. Scalise, 2000. "Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending?," Finance and Economics Discussion Series 2000-39, Board of Governors of the Federal Reserve System (U.S.).

    Cited by:

    1. Ioannidou, Vasso P., 2005. "Does monetary policy affect the central bank's role in bank supervision?," Journal of Financial Intermediation, Elsevier, vol. 14(1), pages 58-85, January.
    2. Berger, Allen N. & Klapper, Leora F. & Udell, Gregory F., 2001. "The ability of banks to lend to informationally opaque small businesses," Journal of Banking & Finance, Elsevier, vol. 25(12), pages 2127-2167, December.
    3. Rai, Anoop & Seth, Rama & Mohanty, Sunil K., 2021. "Foreign bank lending in the U.S. during three U.S. recessions," Global Finance Journal, Elsevier, vol. 48(C).
    4. Marcelo Rezende, 2014. "The Effects of Bank Charter Switching on Supervisory Ratings," Finance and Economics Discussion Series 2014-20, Board of Governors of the Federal Reserve System (U.S.).
    5. Stiroh, Kevin J. & Rumble, Adrienne, 2006. "The dark side of diversification: The case of US financial holding companies," Journal of Banking & Finance, Elsevier, vol. 30(8), pages 2131-2161, August.
    6. Berger,Allen N.,Demirguc-Kunt,Asli, 2021. "Banking Research in the Time of COVID-19," Policy Research Working Paper Series 9782, The World Bank.
    7. Allen N. Berger, 2003. "The institutional memory hypothesis and the procyclicality on bank lending behavior," Proceedings 845, Federal Reserve Bank of Chicago.
    8. Curry, Timothy J. & Fissel, Gary S. & Ramirez, Carlos D., 2008. "The impact of bank supervision on loan growth," The North American Journal of Economics and Finance, Elsevier, vol. 19(2), pages 113-134, August.
    9. Wheeler, P. Barrett, 2019. "Loan loss accounting and procyclical bank lending: The role of direct regulatory actions," Journal of Accounting and Economics, Elsevier, vol. 67(2), pages 463-495.
    10. Ismael Arciniegas Rueda, 2012. "Empirical Analysis Of Speculative Attacks With Contractionary Real Effects," Intelligent Systems in Accounting, Finance and Management, John Wiley & Sons, Ltd., vol. 19(2), pages 102-127, April.
    11. Evanoff, Douglas D. & Jagtiani, Julapa A. & Nakata, Taisuke, 2011. "Enhancing market discipline in banking: The role of subordinated debt in financial regulatory reform," Journal of Economics and Business, Elsevier, vol. 63(1), pages 1-22, January.
    12. Athanasoglou, Panayiotis & Ioannis, Daniilidis & Manthos, Delis, 2013. "Bank procyclicality and output: Issues and policies," MPRA Paper 50830, University Library of Munich, Germany.
    13. Marsh, W. Blake, 2023. "Supervisory stringency, payout restrictions, and bank equity prices," Journal of Banking & Finance, Elsevier, vol. 154(C).
    14. John R. Hall & Thomas B. King & Andrew P. Meyer & Mark D. Vaughan, 2002. "Do jumbo-CD holders care about anything?," Supervisory Policy Analysis Working Papers 2002-05, Federal Reserve Bank of St. Louis.
    15. Curry, Timothy J. & Fissel, Gary S. & Hanweck, Gerald A., 2008. "Is there cyclical bias in bank holding company risk ratings?," Journal of Banking & Finance, Elsevier, vol. 32(7), pages 1297-1309, July.
    16. Bo Sun & Xuan S. Tam & Eric Young, 2020. "The Stock Market Response to a "Regulatory Sine Curve"," International Finance Discussion Papers 1299, Board of Governors of the Federal Reserve System (U.S.).
    17. Krainer, Robert E., 2013. "Towards a program for financial stability," Journal of Economic Behavior & Organization, Elsevier, vol. 85(C), pages 207-218.
    18. Bruggeman, Annick & Donnay, Marie, 2003. "A monthly monetary model with banking intermediation for the euro area," Working Paper Series 264, European Central Bank.
    19. Beverly Hirtle & Anna Kovner & Matthew Plosser, 2016. "The impact of supervision on bank performance," Staff Reports 768, Federal Reserve Bank of New York.
    20. Prateek Sharma, 2022. "Management quality, M-rating, and bank failures," SN Business & Economics, Springer, vol. 2(2), pages 1-32, February.
    21. Munasib Abdul & Roy Devesh & Chen Xing, 2014. "Financial Reforms and International Trade," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 14(4), pages 1237-1281, October.
    22. Krainer, Robert E., 2014. "Monetary policy and bank lending in the Euro area: Is there a stock market channel or an interest rate channel?," Journal of International Money and Finance, Elsevier, vol. 49(PB), pages 283-298.
    23. Elizabeth K. Kiser & Robin A. Prager & Jason R. Scott, 2012. "Supervisor ratings and the contraction of bank lending to small businesses," Finance and Economics Discussion Series 2012-59, Board of Governors of the Federal Reserve System (U.S.).
    24. G. Chiesa, 2001. "Incentive-Based Lendig Capacity, Competition and Regulation in Banking," Working Papers 397, Dipartimento Scienze Economiche, Universita' di Bologna.
    25. Kanas, Angelos, 2013. "Bank dividends, risk, and regulatory regimes," Journal of Banking & Finance, Elsevier, vol. 37(1), pages 1-10.
    26. William F. Bassett & W. Blake Marsh, 2014. "Assessing Targeted Macroprudential Financial Regulation: The Case of the 2006 Commercial Real Estate Guidance for Banks," Finance and Economics Discussion Series 2014-49, Board of Governors of the Federal Reserve System (U.S.).
    27. Krainer, Robert, 2009. "Portfolio and financing adjustments for U.S. banks: Some empirical evidence," Journal of Financial Stability, Elsevier, vol. 5(1), pages 1-24, January.
    28. Radu Muntean, 2009. "Early Warning Models for Banking Supervision in Romania," Advances in Economic and Financial Research - DOFIN Working Paper Series 39, Bucharest University of Economics, Center for Advanced Research in Finance and Banking - CARFIB.
    29. Zhao, Tianshu & Casu, Barbara & Ferrari, Alessandra, 2010. "The impact of regulatory reforms on cost structure, ownership and competition in Indian banking," Journal of Banking & Finance, Elsevier, vol. 34(1), pages 246-254, January.
    30. Bassett, William F. & Lee, Seung Jung & Spiller, Thomas Popeck, 2015. "Estimating changes in supervisory standards and their economic effects," Journal of Banking & Finance, Elsevier, vol. 60(C), pages 21-43.
    31. Chrysovalantis Gaganis & Panagiota Papadimitri & Menelaos Tasiou, 2021. "A multicriteria decision support tool for modelling bank credit ratings," Annals of Operations Research, Springer, vol. 306(1), pages 27-56, November.
    32. Bassett, William F. & Marsh, W. Blake, 2017. "Assessing targeted macroprudential financial regulation: The case of the 2006 commercial real estate guidance for banks," Journal of Financial Stability, Elsevier, vol. 30(C), pages 209-228.
    33. Hans Degryse & Sanja Jakovljević & Steven Ongena, 2015. "A Review of Empirical Research on the Design and Impact of Regulation in the Banking Sector," Annual Review of Financial Economics, Annual Reviews, vol. 7(1), pages 423-443, December.
    34. Berger, Allen N. & Cai, Jin & Roman, Raluca A. & Sedunov, John, 2022. "Supervisory enforcement actions against banks and systemic risk," Journal of Banking & Finance, Elsevier, vol. 140(C).
    35. Panayiotis P. Athanasoglou & Ioannis Daniilidis, 2011. "Procyclicality in the banking industry: causes, consequences and response," Working Papers 139, Bank of Greece.
    36. Anna M. Costello & João Granja & Joseph Weber, 2019. "Do Strict Regulators Increase the Transparency of Banks?," Journal of Accounting Research, Wiley Blackwell, vol. 57(3), pages 603-637, June.
    37. Ishizaka, Alessio & Lokman, Banu & Tasiou, Menelaos, 2021. "A Stochastic Multi-criteria divisive hierarchical clustering algorithm," Omega, Elsevier, vol. 103(C).

Articles

  1. Mercedes Delgado & Margaret Kyle & Anita M. McGahan, 2013. "Intellectual Property Protection and the Geography of Trade," Journal of Industrial Economics, Wiley Blackwell, vol. 61(3), pages 733-762, September.

    Cited by:

    1. Mercedes Campi & Alessandro Nuvolari, 2020. "Intellectual property rights and agricultural development: evidence from a worldwide index of IPRS in agriculture (1961-2018)," Documentos de trabajo del Instituto Interdisciplinario de Economía Política IIEP (UBA-CONICET) 2020-51, Universidad de Buenos Aires, Facultad de Ciencias Económicas, Instituto Interdisciplinario de Economía Política IIEP (UBA-CONICET).
    2. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    3. Campi, Mercedes & Dueñas, Marco, 2016. "Intellectual Property Rights and International Trade of Agricultural Products," World Development, Elsevier, vol. 80(C), pages 1-18.
    4. Yan Yan & Jiatao Li & Jingjing Zhang, 2022. "Protecting intellectual property in foreign subsidiaries: An internal network defense perspective," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 53(9), pages 1924-1944, December.
    5. Mercedes Campi & Marco Duenas & Matteo Barigozzi & Giorgio Fagiolo, 2016. "Do Intellectual Property Rights Influence Cross-Border Mergers and Acquisitions ?," LEM Papers Series 2016/28, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    6. Aseem Kaul & Jiao Luo, 2018. "An economic case for CSR: The comparative efficiency of for‐profit firms in meeting consumer demand for social goods," Strategic Management Journal, Wiley Blackwell, vol. 39(6), pages 1650-1677, June.
    7. Claudia Canals & Michael A. Klein & Fuat Şener, 2023. "Intellectual property‐related preferential trade agreements and US offshoring to developing countries," Review of International Economics, Wiley Blackwell, vol. 31(4), pages 1442-1475, September.
    8. Silvia Balia & Sara Pau & Silvana Robone, 2021. "Intellectual property rights protection and health: the case of tuberculosis," RIEDS - Rivista Italiana di Economia, Demografia e Statistica - The Italian Journal of Economic, Demographic and Statistical Studies, SIEDS Societa' Italiana di Economia Demografia e Statistica, vol. 75(3), pages 149-160, July-Sept.
    9. Martínez-Zarzoso, Inmaculada & Chelala, Santiago, 2020. "Trade agreements and international technology transfer," University of Göttingen Working Papers in Economics 401, University of Goettingen, Department of Economics.
    10. Keith E. Maskus & Lei Yang, 2018. "Domestic patent rights, access to technologies and the structure of exports," Canadian Journal of Economics, Canadian Economics Association, vol. 51(2), pages 483-509, May.
    11. Ridwan Ah Sheikh & Sunil Kanwar, 2024. "Revisiting the Impact of TRIPS on IPR-intensive Export Flows: Evidence from Staggered Difference-in-Differences," Working papers 351, Centre for Development Economics, Delhi School of Economics.
    12. Schankerman, Mark & Galasso, Alberto, 2020. "Licensing Life-Saving Drugs for Developing Countries: Evidence from the Medicines Patent Pool," CEPR Discussion Papers 15544, C.E.P.R. Discussion Papers.
    13. Olena Ivus & Walter G. Park, 2022. "All rights reserved: Copyright protection and multinational knowledge transfers," Economic Inquiry, Western Economic Association International, vol. 60(3), pages 1064-1091, July.
    14. F. Montobbio & A. Primi & Valerio Sterzi, 2015. "IPRs and international knowledge flows: Evidence from six large emerging countries," Post-Print hal-02486325, HAL.
    15. Lin, Jenny X. & Lincoln, William F., 2017. "Pirate's treasure," Journal of International Economics, Elsevier, vol. 109(C), pages 235-245.
    16. Gnangnon, Sèna Kimm, 2022. "Effect of Intellectual Property Rights Protection on Services Export Diversification," EconStor Preprints 248717, ZBW - Leibniz Information Centre for Economics.
    17. Mercedes Delgado & Michael E. Porter & Scott Stern, 2016. "Defining clusters of related industries," Journal of Economic Geography, Oxford University Press, vol. 16(1), pages 1-38.
    18. Brunel, Claire & Zylkin, Thomas, 2019. "Do Cross-border Patents Promote Trade?," MPRA Paper 92514, University Library of Munich, Germany.
    19. Bronwyn H. Hall, 2020. "Patents, Innovation, and Development," NBER Working Papers 27203, National Bureau of Economic Research, Inc.
    20. Mercedes Campi & Marco Dueñas & Matteo Barigozzi & Giorgio Fagiolo, 2019. "Intellectual property rights, imitation, and development. The effect on cross-border mergers and acquisitions," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 28(2), pages 230-256, February.
    21. Ridwan Ah Sheikh & Sunil Kanwar, 2024. "Do Deep Trade Agreements with Intellectual Property Provisions Actually Increase International Trade?," Working papers 344, Centre for Development Economics, Delhi School of Economics.
    22. Shinjinee Chattopadhyay & Janet Bercovitz, 2020. "When one door closes, another door opens … for some: Evidence from the post‐TRIPS Indian pharmaceutical industry," Strategic Management Journal, Wiley Blackwell, vol. 41(6), pages 988-1022, June.
    23. Olena Ivus & Walter Park, 2018. "Patent Reforms and Exporter Behaviour: Firm-Level Evidence from Developing Countries," NBER Chapters, in: Globalization and Welfare Impacts of International Trade, National Bureau of Economic Research, Inc.
    24. Lai, Huiwen & Maskus, Keith E. & Yang, Lei, 2020. "Intellectual property enforcement, exports and productivity of heterogeneous firms in developing countries: Evidence from China," European Economic Review, Elsevier, vol. 123(C).
    25. Alexander Jaax & Sébastien Miroudot, 2021. "Capturing value in GVCs through intangible assets: The role of the trade–investment–intellectual property nexus," Journal of International Business Policy, Palgrave Macmillan, vol. 4(3), pages 433-452, September.
    26. Jayasekara, Dinithi N. & Fredriksson, Per G., 2021. "Culture, intellectual property rights, and technology adoption," The Quarterly Review of Economics and Finance, Elsevier, vol. 80(C), pages 317-330.
    27. Keith E. Maskus & William Ridley, 2016. "Intellectual Property-Related Preferential Trade Agreements and the Composition of Trade," RSCAS Working Papers 2016/35, European University Institute.
    28. Jenny X. Lin & William Lincoln, 2017. "Pirate’s Treasure," Working Papers 17-51, Center for Economic Studies, U.S. Census Bureau.
    29. Damien Dussaux & Antoine Dechezleprêtre & Matthieu Glachant, 2017. "Intellectual property rights protection and the international transfer of low-carbon technologies," Working Papers hal-01693539, HAL.
    30. Wen-Hsien Liu & Hui-Fang Liang, 2016. "Will Domestic Imitative Threats Influence High-Tech Imports? Evidence from Taiwan," Journal of Economics and Management, College of Business, Feng Chia University, Taiwan, vol. 12(1), pages 37-60, February.
    31. Ndubuisi, Gideon, 2019. "Domestic intellectual property rights protection and exports: Accessing the credit channel," MERIT Working Papers 2019-017, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    32. Campi, Mercedes & Dueñas, Marco, 2019. "Intellectual property rights, trade agreements, and international trade," Research Policy, Elsevier, vol. 48(3), pages 531-545.
    33. Bhattacharya, Sourav & Chakraborty, Pavel & Chatterjee, Chirantan, 2022. "Intellectual property regimes and wage inequality," Journal of Development Economics, Elsevier, vol. 154(C).
    34. Léopold BIARDEAU & Anne BORING, 2017. "L’impact de l’aide au développement sur les flux commerciaux entre pays donateurs et pays récipiendaires," Working Paper 464d860e-562e-4ae7-98f5-1, Agence française de développement.
    35. Yan Liu & Walter G. Park & Dahai Fu, 2021. "Export quality and patent protection: Stage‐dependent effects in development," Review of Development Economics, Wiley Blackwell, vol. 25(2), pages 601-629, May.
    36. Thakur–Wernz, Pooja & Wernz, Christian, 2022. "Impact of stronger intellectual property rights regime on innovation: Evidence from de alio versus de novo Indian bio-pharmaceutical firms," Journal of Business Research, Elsevier, vol. 138(C), pages 457-473.
    37. Huiwen Lai & Keith E. Maskus & Lei Yang, 2018. "Intellectual Property Enforcement, Exports and Productivity: Evidence from China," RSCAS Working Papers 2018/39, European University Institute.
    38. Kristin Brandl & Izzet Darendeli & Ram Mudambi, 2019. "Foreign actors and intellectual property protection regulations in developing countries," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 50(5), pages 826-846, July.
    39. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
    40. Sieds, 2021. "Complete Volume LXXV n. 3 2021," RIEDS - Rivista Italiana di Economia, Demografia e Statistica - The Italian Journal of Economic, Demographic and Statistical Studies, SIEDS Societa' Italiana di Economia Demografia e Statistica, vol. 75(3), pages 1-194, July-Sept.
    41. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    42. Ndubuisi, Gideon & Foster-McGregor, Neil, 2018. "Domestic intellectual property rights protection and the margins of bilateral exports," MERIT Working Papers 2018-035, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    43. Wen Chen, 2017. "Do stronger intellectual property rights lead to more R&D-intensive imports?," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 26(7), pages 865-883, October.
    44. Klein, Michael A., 2023. "Trade secret protection, multinational firms and international trade," International Economics, Elsevier, vol. 173(C), pages 325-342.
    45. lv, Kangjuan & Pan, Minjie & Huang, Li & Song, Daqiang & Qian, Xinlei, 2023. "Can intellectual property rights protection reduce air pollution? A quasi-natural experiment from China," Structural Change and Economic Dynamics, Elsevier, vol. 65(C), pages 210-222.
    46. Gnangnon, Sèna Kimm, 2024. "Effects of intellectual property rights protection on services export diversification in developing countries," KDI Journal of Economic Policy, Korea Development Institute (KDI), vol. 46(1), pages 53-89.
    47. Dong, Baomin & Guo, Yibei & Hu, Xiaotian, 2022. "Intellectual property rights protection and export product quality: Evidence from China," International Review of Economics & Finance, Elsevier, vol. 77(C), pages 143-158.

  2. Margaret K. Kyle & Anita M. McGahan, 2012. "Investments in Pharmaceuticals Before and After TRIPS," The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1157-1172, November.
    See citations under working paper version above.
  3. Kyle Margaret, 2011. "Strategic Responses to Parallel Trade," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 11(2), pages 1-34, January.
    See citations under working paper version above.
  4. Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.

    Cited by:

    1. Arzi Adbi & Ajay Bhaskarabhatla & Chirantan Chatterjee, 2020. "Stakeholder Orientation and Market Impact: Evidence from India," Journal of Business Ethics, Springer, vol. 161(2), pages 479-496, January.
    2. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    3. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds," Discussion Paper Series in Economics 4/2023, Norwegian School of Economics, Department of Economics.
    4. Sharat Ganapati & Rebecca McKibbin, 2019. "Non-Tariff Barriers and Bargaining in Generic Pharmaceuticals," Working Papers gueconwpa~18-18-23, Georgetown University, Department of Economics.
    5. Birg, Laura, 2022. "Pharmaceutical Regulation under Market Integration through Parallel Trade," VfS Annual Conference 2022 (Basel): Big Data in Economics 264128, Verein für Socialpolitik / German Economic Association.
    6. Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
    7. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    8. Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
    9. Afschin Gandjour, 2013. "Reference Pricing and Price Negotiations for Innovative New Drugs," PharmacoEconomics, Springer, vol. 31(1), pages 11-14, January.
    10. Giorgio Matteucci & Pierfrancesco Reverberi, 2017. "Drug innovation, price controls, and parallel trade," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 159-179, June.
    11. Antonio Cabrales & Sergi Jiménez-Martín, 2008. "The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really so high?," Working Papers 2008-18, FEDEA.
    12. Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
    13. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
    14. Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
    15. Jorge Guzman & Fiona Murray & Scott Stern & Heidi Williams, 2023. "Accelerating Innovation Ecosystems: The Promise and Challenges of Regional Innovation Engines," NBER Chapters, in: Entrepreneurship and Innovation Policy and the Economy, volume 3, pages 9-75, National Bureau of Economic Research, Inc.
    16. Frank R. Lichtenberg, 2007. "Importation And Innovation," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 16(6), pages 403-417.
    17. Viswanath Pingali & Neelima Das, 2021. "Rare Diseases Require Support Too," Vikalpa: The Journal for Decision Makers, , vol. 46(2), pages 129-134, June.
    18. Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178631, HAL.
    19. Eric W. Bond & Kamal Saggi, 2023. "Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 20, pages 449-480, World Scientific Publishing Co. Pte. Ltd..
    20. Margaret K. Kyle, 2019. "The Single Market in Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 55(1), pages 111-135, August.
    21. Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
    22. Maria Garcia-Alonso & Paul Levine, 2004. "Strategic Procurement, Openness and Market Structure," School of Economics Discussion Papers 0904, School of Economics, University of Surrey.
    23. Dubois, Pierre & Lasio, Laura, 2014. "Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals," IDEI Working Papers 823, Institut d'Économie Industrielle (IDEI), Toulouse.
    24. Klaus Gugler & Florian Szücs, 2023. "Market Power and Regulation in Pharmaceutical Markets," Department of Economics Working Papers wuwp343, Vienna University of Economics and Business, Department of Economics.
    25. Andrea Mantovani & Alireza Naghavi, 2012. "Parallel Imports And Innovation In An Emerging Economy: The Case Of Indian Pharmaceuticals," Health Economics, John Wiley & Sons, Ltd., vol. 21(11), pages 1286-1299, November.
    26. Laura Birg, 2024. "The design of external reference pricing schemes and the choice of reference countries and pricing rules," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 57(4), pages 1182-1202, November.
    27. Kyle Margaret, 2011. "Strategic Responses to Parallel Trade," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 11(2), pages 1-34, January.
    28. Arvate, Paulo Roberto & Barbosa, Klênio & Gambardella, Dante, 2013. "Generic-branded drug competition and the price for pharmaceuticals in procurement auctions," Textos para discussão 333, FGV EESP - Escola de Economia de São Paulo, Fundação Getulio Vargas (Brazil).
    29. Eric Saggi & Saggi Saggi, 2012. "Compulsory licensing, price controls, and access to patented foreign products," Vanderbilt University Department of Economics Working Papers 12-00006, Vanderbilt University Department of Economics.
    30. Schankerman, Mark & Galasso, Alberto, 2020. "Licensing Life-Saving Drugs for Developing Countries: Evidence from the Medicines Patent Pool," CEPR Discussion Papers 15544, C.E.P.R. Discussion Papers.
    31. Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
    32. Patricia M. Danzon & Andrew J. Epstein, 2008. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," NBER Working Papers 14041, National Bureau of Economic Research, Inc.
    33. Margaret Kyle & Heidi Williams, 2016. "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," Post-Print hal-01448505, HAL.
    34. Giorgio Matteucci & Pierfrancesco Reverberi, 2011. "Parallel trade and its impact on incentives to invest in product quality," DIS Technical Reports 2011-05, Department of Computer, Control and Management Engineering, Universita' degli Studi di Roma "La Sapienza".
    35. Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015. "Price regulation and parallel imports of pharmaceuticals," Journal of Public Economics, Elsevier, vol. 129(C), pages 92-105.
    36. Malek, Jan & Newham, Melissa & Seldeslachts, Jo & Veugelers, Reinhilde, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," CEPR Discussion Papers 18816, C.E.P.R. Discussion Papers.
    37. Hernández, Carlos Eduardo & Cantillo-Cleves, Santiago, 2024. "A toolkit for setting and evaluating price floors," Journal of Public Economics, Elsevier, vol. 232(C).
    38. Diego Aparicio & Alberto Cavallo, 2018. "Targeted Price Controls on Supermarket Products," NBER Working Papers 24275, National Bureau of Economic Research, Inc.
    39. Geng, Difei & Saggi, Kamal, 2017. "International effects of national regulations: External reference pricing and price controls," Journal of International Economics, Elsevier, vol. 109(C), pages 68-84.
    40. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
    41. Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2015. "Reference pricing with endogenous generic entry," Discussion Paper Series in Economics 4/2015, Norwegian School of Economics, Department of Economics.
    42. Dewatripont, Mathias, 2022. "Which policies for vaccine innovation and delivery in Europe?," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    43. Anna Rita Bennato & Tommaso Valletti, 2012. "Pharmaceutical Innovation and Parallel Trade," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2012-09, Centre for Competition Policy, University of East Anglia, Norwich, UK..
    44. Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Working Papers 1301, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
    45. Pamina Koenig & Megan Macgarvie, 2009. "Regulatory policy and the location of bio-pharmaceutical FDI in Europe," Working Papers halshs-00566800, HAL.
    46. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-033, Tilburg University, Center for Economic Research.
    47. Volman, Lucas, 2018. "The TRIPS Article 31 Tug of War Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation," LawArXiv 6cxaj, Center for Open Science.
    48. TAKECHI Kazutaka, 2008. "International Strategic Alliances for Local Market Entry: Direct Launches versus Marketing Alliances in Pharmaceuticals," Discussion papers 08022, Research Institute of Economy, Trade and Industry (RIETI).
    49. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
    50. Kamal Saggi, 2016. "Trade, Intellectual Property Rights, and the World Trade Organization," Vanderbilt University Department of Economics Working Papers 16-00014, Vanderbilt University Department of Economics.
    51. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    52. Kurt Brekke & Dag Dalen & Tor Holmås, 2014. "Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
    53. Ivan Mužić & Ivan Žilić, 2023. "Can selective price controls fight off inflation? Lessons from milk products in Croatia," Working Papers 71, The Croatian National Bank, Croatia.
    54. Nicolas Houy & Izabela Jelovac, 2019. "Comparing approval procedures for new drugs," Post-Print halshs-01937219, HAL.
    55. Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
    56. Joan Costa-Font & Alistair McGuire & Nebibe Varol, 2015. "Regulation effects on the adoption of new medicines," Empirical Economics, Springer, vol. 49(3), pages 1101-1121, November.
    57. H. Phoebe Chan, 2010. "The Determinants Of International Patenting For Nine Agricultural Biotechnology Firms," Journal of Industrial Economics, Wiley Blackwell, vol. 58(2), pages 247-278, June.
    58. Birg, Laura, 2019. "Price Caps versus Reimbursement Limits: Pharmaceutical Regulation under Market Integration through Parallel Trade," University of Göttingen Working Papers in Economics 253, University of Goettingen, Department of Economics, revised 2019.
    59. Matthew Grennan & Robert Town, 2015. "Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices," NBER Working Papers 20981, National Bureau of Economic Research, Inc.
    60. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    61. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
    62. Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
    63. Chatterjee, Chirantan & Kubo, Kensuke & Pingali, Viswanath, 2015. "The consumer welfare implications of governmental policies and firm strategy in markets for medicines," Journal of Health Economics, Elsevier, vol. 44(C), pages 255-273.
    64. Cockburn Iain M. & Stern Scott, 2010. "Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy," Capitalism and Society, De Gruyter, vol. 5(1), pages 1-50, July.
    65. Bergman, Mats & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," HUI Working Papers 116, HUI Research.
    66. Michael Kremer & Christopher M. Snyder, 2018. "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals," NBER Working Papers 24206, National Bureau of Economic Research, Inc.
    67. Sabine Vogler, 2019. "Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies," Empirica, Springer;Austrian Institute for Economic Research;Austrian Economic Association, vol. 46(3), pages 443-469, August.
    68. Leemore Dafny & David Dranove, 2009. "Regulatory Exploitation and Management Changes: Upcoding in the Hospital Industry," Journal of Law and Economics, University of Chicago Press, vol. 52(2), pages 223-250, May.
    69. Cédric Schneider, 2011. "The battle for patent rights in plant biotechnology: evidence from opposition fillings," The Journal of Technology Transfer, Springer, vol. 36(5), pages 565-579, October.
    70. Leemore Dafny & David Dranove, 2006. "Regulatory Exploitation and the Market for Corporate Controls," NBER Working Papers 12438, National Bureau of Economic Research, Inc.
    71. Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.
    72. Marta Podemska-Mikluch, 2014. "Public Policy: Object of Choice or Emergent Phenomena? Learning from the Implementation of the Medical Reimbursement Act in Poland," Advances in Austrian Economics, in: Entangled Political Economy, volume 18, pages 93-110, Emerald Group Publishing Limited.
    73. Zhang, Wei & Guh, Daphne P. & Grootendorst, Paul & Hollis, Aidan & Anis, Aslam H., 2024. "The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis," Health Policy, Elsevier, vol. 144(C).
    74. Fritz von der Schulenburg & Sotiris Vandoros & Panos Kanavos, 2011. "The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors," Health Economics Review, Springer, vol. 1(1), pages 1-8, December.
    75. Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
    76. Spicer, Oliver & Grootendorst, Paul, 2022. "The effect of patented drug price on the share of new medicines across OECD countries," Health Policy, Elsevier, vol. 126(8), pages 795-801.
    77. Fabio Pammolli & Armando Rungi, 2016. "Access to Medicines and European Market Integration," Working Papers 01/2016, IMT School for Advanced Studies Lucca, revised Jan 2016.
    78. Mats A. Bergman & David Granlund & Niklas Rudholm, 2017. "Squeezing the Last Drop Out of Your Suppliers: An Empirical Study of Market-Based Purchasing Policies for Generic Pharmaceuticals," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 79(6), pages 969-996, December.
    79. Costa-Font, Joan & McGuire, Alistair & Varol, Nebibe, 2014. "Price regulation and relative delays in generic drug adoption," Journal of Health Economics, Elsevier, vol. 38(C), pages 1-9.
    80. Giorgio Matteucci & Pierfrancesco Reverberi, 2014. "Parallel trade, price regulation, and investment incentives," DIAG Technical Reports 2014-16, Department of Computer, Control and Management Engineering, Universita' degli Studi di Roma "La Sapienza".
    81. Ajay Bhaskarabhatla & Priyatam Anurag & Chirantan Chatterjee & Enrico Pennings, 2021. "How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry," Strategy Science, INFORMS, vol. 6(3), pages 209-227, September.
    82. Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
    83. Verdiana Giannetti & Gaia Rubera, 2020. "Innovation for and from emerging countries: a closer look at the antecedents of trickle-down and reverse innovation," Journal of the Academy of Marketing Science, Springer, vol. 48(5), pages 987-1008, September.
    84. Varol, Nebibe & Costa-i-Font, Joan & McGuire, Alistair, 2010. "Do international launch strategies of pharmaceutical corporations respond to changes in the regulatory environment?," LSE Research Online Documents on Economics 29972, London School of Economics and Political Science, LSE Library.
    85. Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2021. "Innovation And Diffusion Of Medical Treatment," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 62(3), pages 953-1009, August.
    86. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 357, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
    87. Stojchevska, Ivana & Baftijari, Agon, 2015. "The Impact of Governmental Policy on R&D Projects in the Pharmaceutical Industry," Proceedings of the ENTRENOVA - ENTerprise REsearch InNOVAtion Conference (2015), Kotor, Montengero, in: Proceedings of the ENTRENOVA - ENTerprise REsearch InNOVAtion Conference, Kotor, Montengero, 10-11 September 2015, pages 72-79, IRENET - Society for Advancing Innovation and Research in Economy, Zagreb.
    88. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
    89. Clark, Robert & Fabiilli, Christopher & Lasio, Laura, 2022. "Collusion in the US generic drug industry," International Journal of Industrial Organization, Elsevier, vol. 85(C).
    90. Francesca Di Iorio & Maria Letizia Giorgietti, 2019. "Launch of a product and patents: evidence from the US cardiovascular pharmaceutical sector," DEM Working Papers Series 169, University of Pavia, Department of Economics and Management.
    91. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
    92. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
    93. Eric W Bond & Kamal Saggi, 2017. "Price controls versus compulsory licensing: effects on patent-holders and consumers," Vanderbilt University Department of Economics Working Papers 17-00013, Vanderbilt University Department of Economics.
    94. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
    95. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
    96. Stefan Stremersch & Aurélie Lemmens, 2009. "Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes," Marketing Science, INFORMS, vol. 28(4), pages 690-708, 07-08.
    97. Margaret K. Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
    98. Francesca DI IORIO & Maria Letizia GIORGETTI, 2017. "A Deeper Analysis on Pharmaceutical Submarket Concentration: the US market in 1987-1998," Departmental Working Papers 2017-02, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
    99. Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers CERM 02-2012, Competitività, Regole, Mercati (CERM).
    100. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    101. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
    102. Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.
    103. Koenig, Pamina & MacGarvie, Megan, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," Journal of Health Economics, Elsevier, vol. 30(5), pages 950-965.
    104. Vogler, Sabine & Fischer, Stefan, 2020. "How to address medicines shortages: Findings from a cross-sectional study of 24 countries," Health Policy, Elsevier, vol. 124(12), pages 1287-1296.
    105. Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
    106. TAKECHI Kazutaka, 2012. "Negative Effects of Intellectual Property Protection: The unusual suspects?," Discussion papers 12057, Research Institute of Economy, Trade and Industry (RIETI).
    107. Kremer, Michael & Snyder, Christopher, 2018. "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global D," CEPR Discussion Papers 12751, C.E.P.R. Discussion Papers.
    108. Andreas Mense & Claus Michelsen & Konstantin A. Kholodilin, 2019. "Rent Control, Market Segmentation, and Misallocation: Causal Evidence from a Large-Scale Policy Intervention," Discussion Papers of DIW Berlin 1832, DIW Berlin, German Institute for Economic Research.
    109. Stremersch, S. & Lemmens, A., 2008. "Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes," ERIM Report Series Research in Management ERS-2008-026-MKT, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
    110. Geng, Difei & Saggi, Kamal, 2020. "Optimal price regulations in international pharmaceutical markets with generic competition," Journal of Health Economics, Elsevier, vol. 71(C).
    111. Ryan, Michael P., 2010. "Patent Incentives, Technology Markets, and Public-Private Bio-Medical Innovation Networks in Brazil," World Development, Elsevier, vol. 38(8), pages 1082-1093, August.
    112. Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.
    113. Mathias Dewatripont, 2022. "Which Policies for Vaccine Innovation and Delivery in Europe ?," Working Papers ECARES 2022-14, ULB -- Universite Libre de Bruxelles.
    114. Anke Richter, 2008. "Assessing the Impact of Global Price Interdependencies," PharmacoEconomics, Springer, vol. 26(8), pages 649-659, August.
    115. Birg, Laura, 2016. "External reference pricing and the choice of country baskets and pricing rules," University of Göttingen Working Papers in Economics 279, University of Goettingen, Department of Economics.
    116. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.

  5. Henry G. Grabowski & Margaret Kyle, 2007. "Generic competition and market exclusivity periods in pharmaceuticals," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 491-502.

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    2. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
    3. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    4. Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013. "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity," NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 243-271, National Bureau of Economic Research, Inc.
    5. Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
    6. Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
    7. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.
    8. Filson, Darren & Oweis, Ahmed, 2010. "The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(4), pages 575-584, July.
    9. C. Scott Hemphill & Bhaven N. Sampat, 2012. "Weak Patents Are a Weak Deterrent: Patent Portfolios, the Orange Book Listing Standard, and Generic Entry in Pharmaceuticals," NBER Chapters, in: Standards, Patents and Innovations, National Bureau of Economic Research, Inc.
    10. Eric Helland & Seth A. Seabury, 2016. "Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges," NBER Working Papers 22194, National Bureau of Economic Research, Inc.
    11. Böhme, Enrico & Frank, Severin & Kerber, Wolfgang, 2016. "Optimal Incentives for Patent Challenges in the Pharmaceutical Industry," VfS Annual Conference 2016 (Augsburg): Demographic Change 145637, Verein für Socialpolitik / German Economic Association.
    12. Bokhari, Farasat A. S. & Yan, Weijie, 2020. "Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market," Papers WP678, Economic and Social Research Institute (ESRI).
    13. C. Scott Hemphill & Bhaven N. Sampat, 2011. "When Do Generics Challenge Drug Patents?," Journal of Empirical Legal Studies, John Wiley & Sons, vol. 8(4), pages 613-649, December.
    14. Chang, Ching-Wen & Yamanaka, Takayuki & Kano, Shingo, 2019. "An enforced loop-out knowledge flow facilitates industry competition: Learning from the pharmaceutical and genetically modified seed industries," Technovation, Elsevier, vol. 79(C), pages 11-24.
    15. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    16. Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
    17. Hemphill, C. Scott & Sampat, Bhaven N., 2012. "Evergreening, patent challenges, and effective market life in pharmaceuticals," Journal of Health Economics, Elsevier, vol. 31(2), pages 327-339.
    18. Sebastian Böhm & Volker Grossmann & Holger Strulik, 2018. "R&D-Driven Medical Progress, Health Care Costs, and the Future of Human Longevity," CESifo Working Paper Series 6897, CESifo.
    19. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
    20. Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-chong, 2023. "Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis," Journal of Macroeconomics, Elsevier, vol. 76(C).
    21. Mark Trusheim & Murray L. Aitken & Ernst R. Berndt, 2010. "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?," NBER Working Papers 16014, National Bureau of Economic Research, Inc.
    22. Ding, Yucheng & Zhao, Xin, 2019. "Pay-for-delay patent settlement, generic entry and welfare," International Journal of Industrial Organization, Elsevier, vol. 67(C).
    23. Henry Grabowski & Carlos Brain & Anna Taub & Rahul Guha, 2017. "Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes," American Journal of Health Economics, MIT Press, vol. 3(1), pages 33-59, Winter.
    24. Papachristos, George & Adamides, Emmanuel, 2016. "A retroductive systems-based methodology for socio-technical transitions research," Technological Forecasting and Social Change, Elsevier, vol. 108(C), pages 1-14.
    25. Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
    26. Matthew J. Higgins & Mathias J. Kronlund & Ji Min Park & Joshua Pollet, 2020. "The Role of Assets In Place: Loss of Market Exclusivity and Investment," NBER Working Papers 27588, National Bureau of Economic Research, Inc.
    27. Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.
    28. Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
    29. Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
    30. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
    31. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
    32. Severin Frank & Wolfgang Kerber, 2016. "Patent Settlements in the Pharmaceutical Industry: What Can We Learn From Economic Analysis?," MAGKS Papers on Economics 201601, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
    33. Paul F. Skilton & Ednilson Bernardes & Mei Li & Steven A. Creek, 2020. "The Structure of Absorptive Capacity in Three Product Development Strategies," Journal of Supply Chain Management, Institute for Supply Management, vol. 56(3), pages 47-65, July.
    34. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
    35. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    36. Rasmus Arler Bogetoft & Peter Bogetoft, 2022. "Market entrance, patents, and preliminary injunctions: a model of pharmaceutical patent litigation," European Journal of Law and Economics, Springer, vol. 53(3), pages 379-423, June.
    37. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.
    38. Magazzini Laura & Fabio Pammolli & Massimo Riccaboni, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT School for Advanced Studies Lucca, revised Jul 2013.
    39. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    40. Phill O’Neill & Jorge Mestre-Ferrandiz & Ruth Puig-Peiro & Jon Sussex, 2013. "Projecting Expenditure on Medicines in the UK NHS," PharmacoEconomics, Springer, vol. 31(10), pages 933-957, October.
    41. Wrona, Thomas & Trąpczyński, Piotr, 2012. "Re-explaining international entry modes – Interaction and moderating effects on entry modes of pharmaceutical companies into transition economies," European Management Journal, Elsevier, vol. 30(4), pages 295-315.

  6. Margaret K. Kyle, 2006. "The role of firm characteristics in pharmaceutical product launches," RAND Journal of Economics, RAND Corporation, vol. 37(3), pages 602-618, September.

    Cited by:

    1. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    2. Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
    3. Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
    4. Francesca Di Iorio & Maria Letizia Giorgetti, 2018. "The impact of submarket concentration in the US pharmaceutical industry in 1987-1998," DEM Working Papers Series 163, University of Pavia, Department of Economics and Management.
    5. Iain M. Cockburn & Megan J. MacGarvie, 2006. "Entry and Patenting in the Software Industry," NBER Working Papers 12563, National Bureau of Economic Research, Inc.
    6. Melisa Newham & Jo Seldeslachts & Albert Banal-Estañol, 2018. "Common ownership and market entry: Evidence from the pharmaceutical industry," Economics Working Papers 1612, Department of Economics and Business, Universitat Pompeu Fabra.
    7. Branko Bo_skovic, David. P. Byrne, Arvind Magesan, 2012. "Herding Among Bureaucrats," Department of Economics - Working Papers Series 1153, The University of Melbourne.
    8. Arvate, Paulo Roberto & Barbosa, Klênio & Gambardella, Dante, 2013. "Generic-branded drug competition and the price for pharmaceuticals in procurement auctions," Textos para discussão 333, FGV EESP - Escola de Economia de São Paulo, Fundação Getulio Vargas (Brazil).
    9. Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
    10. Patricia M. Danzon & Andrew J. Epstein, 2008. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," NBER Working Papers 14041, National Bureau of Economic Research, Inc.
    11. Ernst R. Berndt & Patricia M. Danzon & Gregory B. Kruse, 2007. "Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 231-250.
    12. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
    13. Pamina Koenig & Megan Macgarvie, 2009. "Regulatory policy and the location of bio-pharmaceutical FDI in Europe," Working Papers halshs-00566800, HAL.
    14. TAKECHI Kazutaka, 2008. "International Strategic Alliances for Local Market Entry: Direct Launches versus Marketing Alliances in Pharmaceuticals," Discussion papers 08022, Research Institute of Economy, Trade and Industry (RIETI).
    15. Joan Costa-Font & Alistair McGuire & Nebibe Varol, 2015. "Regulation effects on the adoption of new medicines," Empirical Economics, Springer, vol. 49(3), pages 1101-1121, November.
    16. Gianni Amisano & Maria Letizia Giorgetti, 2005. "Entry in Pharmaceutical submarkets: A Bayesian Panel Probit Approach," Working Papers ubs0511, University of Brescia, Department of Economics.
    17. H. Phoebe Chan, 2010. "The Determinants Of International Patenting For Nine Agricultural Biotechnology Firms," Journal of Industrial Economics, Wiley Blackwell, vol. 58(2), pages 247-278, June.
    18. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    19. Li, Ying & Jin, Yanhong H., 2009. "Racing to market leadership: Product launch and upgrade decisions," International Journal of Production Economics, Elsevier, vol. 119(2), pages 284-297, June.
    20. Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
    21. Bergman, Mats & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," HUI Working Papers 116, HUI Research.
    22. Jan Niederreiter, 2023. "Broadening Economics in the Era of Artificial Intelligence and Experimental Evidence," Italian Economic Journal: A Continuation of Rivista Italiana degli Economisti and Giornale degli Economisti, Springer;Società Italiana degli Economisti (Italian Economic Association), vol. 9(1), pages 265-294, March.
    23. Hirai, Yuka & Yamanaka, Yosuke & Kusama, Makiko & Ishibashi, Taro & Sugiyama, Yuichi & Ono, Shunsuke, 2012. "Analysis of the success rates of new drug development in Japan and the lag behind the US," Health Policy, Elsevier, vol. 104(3), pages 241-246.
    24. Spicer, Oliver & Grootendorst, Paul, 2022. "The effect of patented drug price on the share of new medicines across OECD countries," Health Policy, Elsevier, vol. 126(8), pages 795-801.
    25. Fabio Pammolli & Armando Rungi, 2016. "Access to Medicines and European Market Integration," Working Papers 01/2016, IMT School for Advanced Studies Lucca, revised Jan 2016.
    26. Ting Zhu & Vishal Singh, 2009. "Spatial competition with endogenous location choices: An application to discount retailing," Quantitative Marketing and Economics (QME), Springer, vol. 7(1), pages 1-35, March.
    27. Mats A. Bergman & David Granlund & Niklas Rudholm, 2017. "Squeezing the Last Drop Out of Your Suppliers: An Empirical Study of Market-Based Purchasing Policies for Generic Pharmaceuticals," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 79(6), pages 969-996, December.
    28. Verdiana Giannetti & Gaia Rubera, 2020. "Innovation for and from emerging countries: a closer look at the antecedents of trickle-down and reverse innovation," Journal of the Academy of Marketing Science, Springer, vol. 48(5), pages 987-1008, September.
    29. Luke M. Olson & Brett W. Wendling, 2018. "Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 139-172, August.
    30. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 357, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
    31. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
    32. Gianni Amisano & Maria Letizia Giorgetti, 2013. "Entry Into Pharmaceutical Submarkets: A Bayesian Panel Probit Analysis," Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 28(4), pages 667-701, June.
    33. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
    34. Maria Letizia GIORGETTI & Maria Luisa MANCUSI, 2016. "Entry and Patenting in the Pharmaceutical Industry," Departmental Working Papers 2016-02, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
    35. Barbosa, Klenio & Silva, Everton, 2017. "The Pattern of Entry of Generic Drugs into the Brazilian Pharmaceutical Market," Brazilian Review of Econometrics, Sociedade Brasileira de Econometria - SBE, vol. 37(1), May.
    36. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
    37. Francesca DI IORIO & Maria Letizia GIORGETTI, 2017. "A Deeper Analysis on Pharmaceutical Submarket Concentration: the US market in 1987-1998," Departmental Working Papers 2017-02, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
    38. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
    39. Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.
    40. Koenig, Pamina & MacGarvie, Megan, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," Journal of Health Economics, Elsevier, vol. 30(5), pages 950-965.
    41. TAKECHI Kazutaka, 2012. "Negative Effects of Intellectual Property Protection: The unusual suspects?," Discussion papers 12057, Research Institute of Economy, Trade and Industry (RIETI).

  7. Davina C. Ling & Ernst R. Berndt & Margaret K. Kyle, 2002. "Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 691-723.

    Cited by:

    1. Meltem Daysal N. & Orsini Chiara, 2015. "Spillover Effects of Drug Safety Warnings on Preventive Health Care Use," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 15(1), pages 179-208, January.
    2. Kurt R. Brekke & Michael Kuhn, 2005. "Direct to Consumer Advertising in Pharmaceutical Markets," CESifo Working Paper Series 1493, CESifo.
    3. Dhaval M. Dave, 2013. "Effects of Pharmaceutical Promotion: A Review and Assessment," NBER Working Papers 18830, National Bureau of Economic Research, Inc.
    4. John Cawley & John A. Rizzo, 2005. "The Competitive Effects of Drug Withdrawals," NBER Working Papers 11223, National Bureau of Economic Research, Inc.
    5. Anusua Datta & Dhaval Dave, 2017. "Effects of Physician‐directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence," Health Economics, John Wiley & Sons, Ltd., vol. 26(4), pages 450-468, April.
    6. Meredith B. Rosenthal & Ernst R. Berndt & Julie M. Donohue & Arnold M. Epstein & Richard G. Frank, 2003. "Demand Effects of Recent Changes in Prescription Drug Promotion," NBER Chapters, in: Frontiers in Health Policy Research, Volume 6, pages 1-26, National Bureau of Economic Research, Inc.
    7. Meltem Daysal, N. & Orsini, C., 2012. "Spillover Effects of Drug Safety Warnings on Health Behavior," Other publications TiSEM c6e7afb0-f661-4cf3-86f8-1, Tilburg University, School of Economics and Management.
    8. Matear, Margaret & Dacin, Peter A., 2010. "Marketing and societal welfare: A multiple stakeholder approach," Journal of Business Research, Elsevier, vol. 63(11), pages 1173-1178, November.
    9. Deiana, C. & Giua, L. & Nisticò, R., 2020. "Opium Price Shocks and Prescription Opioids in the US," Health, Econometrics and Data Group (HEDG) Working Papers 20/23, HEDG, c/o Department of Economics, University of York.
    10. Dhaval Dave & Henry Saffer, 2010. "The Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand," NBER Working Papers 15969, National Bureau of Economic Research, Inc.
    11. Matthew Ryan & Rhema Vaithianathan, 2015. "The Regulation of Direct-to-Consumer Advertising of Pharmaceuticals in a Managed Care Setting," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 17(6), pages 986-1021, December.
    12. Hosken, Daniel & Wendling, Brett, 2013. "Informing the uninformed: How drug advertising affects check-up visits," International Journal of Industrial Organization, Elsevier, vol. 31(2), pages 181-194.
    13. Kremer, Sara T.M. & Bijmolt, Tammo H.A. & Leeflang, Peter S.H. & Wieringa, Jaap E., 2008. "Generalizations on the effectiveness of pharmaceutical promotional expenditures," International Journal of Research in Marketing, Elsevier, vol. 25(4), pages 234-246.
    14. Bart J. Bronnenberg & Jean-Pierre H. Dube & Matthew Gentzkow, 2012. "The Evolution of Brand Preferences: Evidence from Consumer Migration," American Economic Review, American Economic Association, vol. 102(6), pages 2472-2508, October.
    15. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 357, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
    16. Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley, 2013. "Pharmaceutical Followers," NBER Working Papers 19522, National Bureau of Economic Research, Inc.
    17. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
    18. Peter Leeflang & Jaap Wieringa, 2010. "Modeling the effects of pharmaceutical marketing," Marketing Letters, Springer, vol. 21(2), pages 121-133, June.
    19. Svetlana Beilfuss & Sebastian Linde, 2021. "Pharmaceutical opioid marketing and physician prescribing behavior," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3159-3185, December.
    20. Rosemary Avery & Donald Kenkel & Dean Lillard & Alan Mathios, 2007. "Regulating advertisements: the case of smoking cessation products," Journal of Regulatory Economics, Springer, vol. 31(2), pages 185-208, April.
    21. Eaves, Emery R., 2015. "“Just Advil”: Harm reduction and identity construction in the consumption of over-the-counter medication for chronic pain," Social Science & Medicine, Elsevier, vol. 146(C), pages 147-154.
    22. Chatterjee, Chirantan & Joshi, Radhika & Sood, Neeraj & Boregowda, P., 2018. "Government health insurance and spatial peer effects: New evidence from India," Social Science & Medicine, Elsevier, vol. 196(C), pages 131-141.
    23. Avery, Rosemary J. & Eisenberg, Matthew D. & Simon, Kosali I., 2012. "The impact of direct-to-consumer television and magazine advertising on antidepressant use," Journal of Health Economics, Elsevier, vol. 31(5), pages 705-718.
    24. Su Liu & Deborah Chollet, "undated". "Price and Income Elasticity of the Demand for Health Insurance and Health Care Services: A Critical Review of the Literature," Mathematica Policy Research Reports dbf03ba11863430593b0b825f, Mathematica Policy Research.
    25. Rosemary Avery & Donald Kenkel & Dean R. Lillard & Alan Mathios, 2006. "Private Profits and Public Health: Does Advertising Smoking Cessation Products Encourage Smokers to Quit?," NBER Working Papers 11938, National Bureau of Economic Research, Inc.
    26. Davina C. Ling & Ernst R. Berndt & Richard G. Frank, 2008. "Economic Incentives And Contracts: The Use Of Psychotropic Medications," Contemporary Economic Policy, Western Economic Association International, vol. 26(1), pages 49-72, January.
    27. Stefan Stremersch & Vardit Landsman & Sriram Venkataraman, 2013. "The Relationship Between DTCA, Drug Requests, and Prescriptions: Uncovering Variation in Specialty and Space," Marketing Science, INFORMS, vol. 32(1), pages 89-110, June.
    28. Andrew Epstein & Scott Johnson, 2012. "Physician response to financial incentives when choosing drugs to treat breast cancer," International Journal of Health Economics and Management, Springer, vol. 12(4), pages 285-302, December.
    29. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.

Software components

    Sorry, no citations of software components recorded.

Chapters

  1. Jeffrey L. Furman & Margaret K. Kyle & Iain Cockburn & Rebecca M. Henderson, 2010. "Public and Private Spillovers: Location and the Productivity of Pharmaceutical Research," NBER Chapters, in: Contributions in Memory of Zvi Griliches, pages 165-188, National Bureau of Economic Research, Inc.

    Cited by:

    1. Elisa Giuliani & Arianna Martinelli & Roberta Rabellotti, 2015. "Is Co-Invention Expediting Technological Catch Up? A Study of Collaboration between Emerging Country Firms and EU inventors," LEM Papers Series 2015/10, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    2. Iain M. Cockburn & Matthew J. Slaughter, 2010. "The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions," NBER Chapters, in: Innovation Policy and the Economy, Volume 10, pages 129-157, National Bureau of Economic Research, Inc.
    3. Nishimura, Junichi & Okamuro, Hiroyuki, 2012. "Subsidy and networking: The effects of direct and indirect support programs of the cluster policy," Working Paper Series 22, Center for Interfirm Network, Institute of Economic Research, Hitotsubashi University.
    4. Hiroyuki Okamuro & Junichi Nishimura, 2013. "Impact of university intellectual property policy on the performance of university-industry research collaboration," The Journal of Technology Transfer, Springer, vol. 38(3), pages 273-301, June.
    5. René Belderbos & Bart Leten & Shinya Suzuki, 2017. "Scientific research, firm heterogeneity, and foreign R&D locations of multinational firms," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 26(3), pages 691-711, September.
    6. T. Ravichandran & Shu Han & Sunil Mithas, 2017. "Mitigating Diminishing Returns to R&D: The Role of Information Technology in Innovation," Information Systems Research, INFORMS, vol. 28(4), pages 812-827, December.
    7. Rene Belderbos & Bart Leten & Shinya Suzuki, 2009. "Does Excellence in Academic Research Attract Foreign R&D?," Global COE Hi-Stat Discussion Paper Series gd09-079, Institute of Economic Research, Hitotsubashi University.
    8. Chris Forman & Nicolas van Zeebroeck, 2012. "From Wires to Partners: How the Internet Has Fostered R&D Collaborations Within Firms," Management Science, INFORMS, vol. 58(8), pages 1549-1568, August.
    9. Bettina Becker, 2013. "The Determinants of R&D Investment: A Survey of the Empirical Research," Discussion Paper Series 2013_09, Department of Economics, Loughborough University, revised Sep 2013.
    10. Laura Abramovsky, 2015. "Global engagement in R&D: a portrait of biopharmaceutical patenting firms," IFS Working Papers W15/18, Institute for Fiscal Studies.
    11. Isabel Tecu, 2013. "The Location of Industrial Innovation: Does Manufacturing Matter?," Working Papers 13-09, Center for Economic Studies, U.S. Census Bureau.
    12. Okamuro, Hiroyuki & Nishimura, Junichi, 2011. "Management of Cluster Policies: Case Studies of Japanese, German, and French Bio-clusters," CEI Working Paper Series 2011-7, Center for Economic Institutions, Institute of Economic Research, Hitotsubashi University.
    13. Picone, Gabriel A. & Ridley, David B. & Zandbergen, Paul A., 2009. "Distance decreases with differentiation: Strategic agglomeration by retailers," International Journal of Industrial Organization, Elsevier, vol. 27(3), pages 463-473, May.
    14. Catini, Roberto & Karamshuk, Dmytro & Penner, Orion & Riccaboni, Massimo, 2015. "Identifying geographic clusters: A network analytic approach," Research Policy, Elsevier, vol. 44(9), pages 1749-1762.

  2. Ernst R. Berndt & Margaret Kyle & Davina Ling, 2003. "The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches," NBER Chapters, in: Scanner Data and Price Indexes, pages 229-267, National Bureau of Economic Research, Inc.

    Cited by:

    1. Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
    2. Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
    3. Haiden Huskamp & Julie Donohue & Catherine Koss & Ernst Berndt & Richard Frank, 2008. "Generic Entry, Reformulations and Promotion of SSRIs in the US," PharmacoEconomics, Springer, vol. 26(7), pages 603-616, July.
    4. Eric Helland & Seth A. Seabury, 2016. "Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges," NBER Working Papers 22194, National Bureau of Economic Research, Inc.
    5. Meredith B. Rosenthal & Ernst R. Berndt & Julie M. Donohue & Arnold M. Epstein & Richard G. Frank, 2003. "Demand Effects of Recent Changes in Prescription Drug Promotion," NBER Chapters, in: Frontiers in Health Policy Research, Volume 6, pages 1-26, National Bureau of Economic Research, Inc.
    6. Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.
    7. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
    8. Daniel Melser & Iqbal A. Syed, 2016. "Life Cycle Price Trends and Product Replacement: Implications for the Measurement of Inflation," Review of Income and Wealth, International Association for Research in Income and Wealth, vol. 62(3), pages 509-533, September.
    9. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-033, Tilburg University, Center for Economic Research.
    10. Berndt, Ernst R. & Gibbons, Robert S. & Kolotilin, Anton & Taub, Anna Levine, 2015. "The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics," Journal of Health Economics, Elsevier, vol. 40(C), pages 26-39.
    11. Iqbal Syed & Daniel Melser, 2008. "Prices over the Product Life Cycle: An Empirical Analysis," Discussion Papers 2008-25, School of Economics, The University of New South Wales.
    12. Mason, Charles F. & Phillips, Owen R., 2016. "Imminent entry and the transition to multimarket rivalry in a laboratory setting," LSE Research Online Documents on Economics 68888, London School of Economics and Political Science, LSE Library.
    13. Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
    14. Ana Aizcorbe & Nicole Nestoriak, 2010. "Price Indexes for Drugs: A Review of the Issues," BEA Working Papers 0050, Bureau of Economic Analysis.
    15. Jie Chen & John Rizzo, 2012. "Pricing dynamics and product quality: the case of antidepressant drugs," Empirical Economics, Springer, vol. 42(1), pages 279-300, February.
    16. Daniel Melser & Iqbal A. Syed, 2016. "The Product Life Cycle and Sample Representativity Bias in Price Indexes," Discussion Papers 2016-07, School of Economics, The University of New South Wales.
    17. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 357, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
    18. Melser, Daniel & Syed, Iqbal, 2007. "Life Cycle Pricing and the Measurement of Inflation," MPRA Paper 16722, University Library of Munich, Germany, revised 07 Jul 2008.
    19. Holtrop, Niels & Wieringa, Jakob & Gijsenberg, Maarten & Stern, P., 2016. "Competitive reactions to personal selling," Research Report 16004-MARK, University of Groningen, Research Institute SOM (Systems, Organisations and Management).
    20. Regan, Tracy L., 2008. "Generic entry, price competition, and market segmentation in the prescription drug market," International Journal of Industrial Organization, Elsevier, vol. 26(4), pages 930-948, July.
    21. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
    22. Daniel Melser & Iqbal A. Syed, 2013. "Prices over the Product Life Cycle: Implications for Quality-Adjustment and the Measurement of Inflation," Discussion Papers 2013-26, School of Economics, The University of New South Wales.
    23. Siotis, Georges & Castanheira, Micael & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2017. "The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma," CEPR Discussion Papers 11813, C.E.P.R. Discussion Papers.
    24. Sara Parker‐Lue, 2020. "The impact of reducing pharmaceutical industry payments on physician prescribing," Health Economics, John Wiley & Sons, Ltd., vol. 29(3), pages 382-390, March.
    25. Ernst R. Berndt, 2002. "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 45-66, Fall.

  3. Allen N. Berger & Margaret K. Kyle & Joseph M. Scalise, 2001. "Did US Bank Supervisors Get Tougher during the Credit Crunch? Did They Get Easier during the Banking Boom? Did It Matter to Bank Lending?," NBER Chapters, in: Prudential Supervision: What Works and What Doesn't, pages 301-356, National Bureau of Economic Research, Inc.
    See citations under working paper version above.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.